Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

Drug Discovery World

JANUARY 16, 2024

Dr Masaru Kanekiyo On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH.

Vaccination 64

Vaccination Vaccine Allergies Protein 64

Medical Xpress

APRIL 13, 2023

In November 2022, the National Institute of Allergy and Infectious Diseases (NIAID) co-hosted a virtual workshop on the importance and challenges of developing mucosal vaccines for SARS-COV-2. The highlights of this workshop have now been published as a report in npj Vaccines.

Vaccination 74

Vaccination Vaccine Allergies Development 74

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

pharmaphorum

MARCH 23, 2021

AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a representative view of its efficacy. AstraZeneca is preparing to file this and other trial data with the FDA asking for an emergency approval of the vaccine.

Vaccination 98

Vaccination Vaccine Trials Allergies 98

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccination 52

Vaccination Vaccine Trials Antibody 52

Scienmag

JANUARY 11, 2021

Scientists reach new milestone in vaccine development for neglected tropical disease Researchers have taken an important step forward in developing a controlled human infection model to test leishmaniasis vaccines.

Scientist 40

Scientist Vaccination Vaccine Development 40

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccination 52

Vaccination Vaccine Trials Development 52

Scienmag

SEPTEMBER 30, 2020

Credit: Stefan Zimmerman Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age. That is according to a large study by researchers at Karolinska Institutet in Sweden published in New England Journal of Medicine.

Vaccination 97

Vaccination Vaccine Medicine Development 97

Scienmag

SEPTEMBER 3, 2020

A team at the George Washington University Vaccine Research Unit has developed a controlled human hookworm infection model, accelerating the development of human hookworm vaccines WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model (..)

Vaccination 68

Vaccination Vaccine Research Development 68

XTalks

NOVEMBER 16, 2020

Moderna announced today that its highly anticipated COVID-19 vaccine candidate appears to be 94.5 The news comes shortly after Pfizer and BioNTech’s mega announcement last week of their COVID-19 vaccine having shown 90 percent efficacy in an ongoing large-scale Phase III trial. The vaccine is given in two doses.

Vaccination 105

Vaccination Vaccine Trials Allergies 105

Pharmaceutical Technology

MAY 16, 2023

It will benefit from Omega’s newly opened injectable manufacturing facility, which has received clearances from Health Canada and the US Food and Drug Administration, as well as from Juno’s commercial network and product development pipeline.

Cosmetics 130

Cosmetics Allergies Manufacturing Production 130

Scienmag

NOVEMBER 4, 2020

The finding provides a surrogate for testing the effectiveness of vaccine candidates Credit: Jennifer Jenks, Duke University School of Medicine DURHAM, N.C.

Vaccination 63

Vaccination Vaccine Research Development 63

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 22, 2020

Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273. The randomized, placebo-controlled trial is being conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and HHS’ Biomedical Advanced Research and Development Authority.

Vaccination 52

Vaccination Vaccine Trials Allergies 52

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […]. UNIVERSITY PARK, Pa.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization. THURSDAY, Dec.

Vaccination 52

Vaccination Vaccine Allergies Clinical Trials 52

The Pharma Data

JANUARY 29, 2021

29, 2021 — Interim phase 3 data show that the COVID-19 vaccine developed by Janssen Pharmaceuticals of Johnson & Johnson is 66 percent effective in preventing moderate-to-severe COVID-19 in adults, the National Institutes of Health announced today. The vaccine, known as Ad.26.COV2.S, The vaccine, known as Ad.26.COV2.S,

Vaccination 52

Vaccination Vaccine Allergies Clinical Trials 52

The Pharma Data

NOVEMBER 16, 2020

Moderna Vaccine Shows 94.5 announced on Monday that early results show its COVID-19 vaccine is 94.5 The researchers behind the vaccine said the results were far better than they had hoped. The Moderna vaccine results were analyzed by an independent data safety monitoring board, appointed by the U.S. Professional.

Vaccination 52

Vaccination Vaccine Allergies Research 52

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Scienmag

JANUARY 8, 2021

Kim focused on developing vaccines for HIV, Ebola and pandemic influenza. But, within days of closing their campus lab space as part of COVID-19 precautions, they turned their attention to a vaccine for SARS-CoV-2, the virus that causes COVID-19. Although the […].

Vaccination 57

Vaccination Vaccine Development Allergies 57

The Pharma Data

OCTOBER 21, 2020

Fauci ‘Cautiously Optimistic’ for COVID-19 Vaccine by Year’s End. the leading infectious disease expert in the United States, said on Wednesday he is “cautiously optimistic” that a COVID-19 vaccine will be ready by year’s end. Multiple studies are testing three vaccine approaches, Fauci said.

Vaccination 52

Vaccination Vaccine Allergies Trials 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.

Vaccination 53

Vaccination Vaccine Trials Immune Response 53

Scienmag

MARCH 24, 2021

Governments should prioritise surgical patients for COVID-19 vaccination Patients waiting for elective surgery should get COVID-19 vaccines ahead of the general population – potentially helping to avoid thousands of post-operative deaths linked to the virus, according to a new study funded by the NIHR. Between 0.6%

Vaccination 71

Vaccination Vaccine Development Allergies 71

Scienmag

MARCH 2, 2021

New Cleveland Clinic-led research published in mBio Credit: Cleveland Clinic CLEVELAND – Researchers from Cleveland Clinic’s Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

Vaccination 59

Vaccination Vaccine Research Development 59

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

Drug Discovery World

JANUARY 12, 2024

Research reveals an immune cell that can kill all cancers Researchers in the US have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Immune Response Allergies Bacteria 52